Malta - İngilizce - HMA (Heads of Medicines Agencies)

intervet intenational bv - mycoplasma hyopneumoniae active principles 0 % - suspension for injection - pigs food - mycoplasma vaccine

Hollanda - İngilizce - HMA (Heads of Medicines Agencies)

intervet intenational bv - mycoplasma hyopneumoniae active principles 0 % - suspension for injection - pigs food - mycoplasma vaccine

Portekiz - İngilizce - HMA (Heads of Medicines Agencies)

intervet intenational bv - mycoplasma hyopneumoniae active principles 0 % - suspension for injection - pigs food - mycoplasma vaccine

Birleşik Krallık - İngilizce - HMA (Heads of Medicines Agencies)

intervet intenational bv - mycoplasma hyopneumoniae active principles 0 % - suspension for injection - pigs food - mycoplasma vaccine

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologicals for suidae - pigs (for fattening) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d.active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inactivated viral and inactivated bacterial vaccines - pigs - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.for active immunisation of pigs over the age of 3 weeks against mycoplasma hyopneumoniae to reduce lung lesions caused by infection with m. hyopneumoniae.

Yeni Zelanda - İngilizce - Ministry for Primary Industries

boehringer ingelheim animal health new zealand limited - mycoplasma hyopneumoniae - mycoplasma hyopneumoniae 0 vaccine - vaccine

Yeni Zelanda - İngilizce - Ministry for Primary Industries

schering-plough animal health limited - mycoplasma hyopneumoniae; porcine circovirus type 2 orf-2 protein - mycoplasma hyopneumoniae 0 vaccine; porcine circovirus type 2 orf-2 protein 0 vaccine - vaccine

Avustralya - İngilizce - APVMA (Australian Pesticides and Veterinary Medicines Authority)

alltech lienert australia pty ltd - oxytetracycline hydrochloride - oral powder, pre-mix - oxytetracycline hydrochloride antibiotic active 200.0 g/kg - nutrition & metabolism - pigs | boar | gilt | piglet | sow | swine - mycoplasma hyopneumoniae | reduction of lung lesions | respiratory disease | swine enzootic pneumonia

Birleşik Krallık - İngilizce - VMD (Veterinary Medicines Directorate)

eli lilly and company limited - mycoplasma hyopneumoniae - emulsion for injection - inactivated bacterial vaccine - pigs